A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets (Epilepsy)

July 9, 2013 updated by: Vince & Associates Clinical Research, Inc.

An Open Label, Randomized, Four-period, Two-sequence, Fully Replicated, Single-dose, Crossover Study of the Relative Bioavailability of Two Formulations of Extended-release Divalproex Sodium Tablets in Fed Patients With Stable Epilepsy.

A study in stable epilepsy patients comparing levels of valproic acid after administration of brand and generic divalproex sodium extended release tablets.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Study consists of a screening visit, four treatment periods and a final follow-up visit. Each treatment period consists of a four night in-house stay followed by two outpatient visits. Each treatment period will be separated by a washout period. During each treatment period, safety evaluations will include vital signs, physical exams, safety laboratory tests, weight measurement, electrocardiograms, adverse event collection and concomitant medication recording. Pharmacokinetic blood samples will be collected during each treatment period. Seizure activity will be recorded in a seizure diary during the study. A standardized high-fat, high-calorie meal will be served prior to each dose during each treatment period.

Study Type

Interventional

Enrollment (Anticipated)

16

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Kansas
      • Overland Park, Kansas, United States, 66212
        • Recruiting
        • Vince & Associates Clinical Research, Inc.
        • Contact:
        • Principal Investigator:
          • Bradley D Vince, DO

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 51 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Able to understand, sign and date the informed consent form
  • Male or female 18 to 55 years old with a diagnosis of epilepsy who are stable
  • Body mass 18 to 34 kg/m, inclusive
  • Is continuously receiving a fixed dose of their AED medication(s)for a minimum of 30 days prior to screening
  • Stay on the same dosages of their routine concomitant medications throughout the study
  • Healthy, as determined by pre-study medical history, vital signs, physical exam, ECG and the opinion of the investigator
  • Normal renal function per laboratory test
  • No clinically relevant labs.
  • Negative for hepatitis B, C and HIV
  • For females, negative pregnancy test
  • Negative for drugs of abuse and alcohol
  • Nonsmoker or has not smoked within the past six months.
  • Some over-the-counter medications may be permitted at the discretion of the investigator
  • Able to communicate well and comply with study procedures, requirements and restrictions

Exclusion Criteria:

  • History or presence of clinically significant medical disorders
  • Have a current psychiatric disorder
  • History of status epilepticus within 90 days of screening
  • Any other condition that the investigator would feel could interfere with the safety of the subject or the study protocol.
  • Taking three or more AED medications
  • Use of felbamate, aspirin, carbapenem antibiotics, rifampin, ritonavir, macrolide antibiotics, cholestyramine, and/or risperidone.
  • Use of any investigational agent or medical device within 30 days of screening.
  • History of clinically significant drug allergy that in the opinion of the investigator may compromise the subject's safety or study results.
  • History of known hypersensitivity to divalproex sodium or its excipients
  • History of alcohol or drug abuse or dependence in the past 5 years
  • Consumed alcohol, caffeine or other xanthine-containing foods or beverages within 48 hours prior to each clinic admission.
  • Consumed grapefruit and/or grapefruit containing products within days prior to admission to the clinic on Day -1 and they agree not to consume grapefruit and/or grapefruit containing products for the duration of their study involvement
  • Participated in any strenuous physical exercise within 72 hours before admission to the clinic on Day 1 and agrees to abstain from the duration of their study involvement.
  • Acute illness at screening and/or at admission to the clinic
  • Lactose intolerance or unusual dietary habits.
  • Blood donation within 8 weeks of admission to this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Divalproex Sodium Extended Release 250mg
Treatment A: A single 2-tablet dose of divalproex sodium extended-release tablet, 250mg. Each subject will have 2 treatments with this medication and two treatments with a single 2-tablet dose of DEPAKOTE 250mg tablet.
Drug: Divalproex Sodium Extended-release 250mg
Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
Other Names:
  • DEPAKOTE 250mg
Drug: DEPAKOTE 250mg
Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
Other Names:
  • Divalproex Sodium Extended-Release 250mg
Active Comparator: DEPAKOTE 250mg
Treatment B: A single 2-tablet dose of DEPAKOTE ER tablet, 250mg. Each subject will have 2 treament period with this medication and 2 treatment periods with a single 2-tablet dose of Divalproex Sodium Extended-Release 250mg tablet.
Drug: Divalproex Sodium Extended-release 250mg
Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
Other Names:
  • DEPAKOTE 250mg
Drug: DEPAKOTE 250mg
Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
Other Names:
  • Divalproex Sodium Extended-Release 250mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate generic divalproex sodium extended release to Depakote ER
Time Frame: Approximately 2.5 months
This is an open-label, randomized, two-sequence, two-treatment, single dose, four-period, fully replicated crossover study in which 16 subjects will receive one of the two study drugs, Depakote ER or a generic equivalent, during each treatment period. Subjects will be patients with epilepsy who are otherwise healthy and who are stable on anti-epileptic therapy, not including any formulation of divalproex sodium.
Approximately 2.5 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Vince & Associates Clinical Research, Inc.

Collaborators

Food and Drug Administration (FDA)

Investigators

  • Principal Investigator: Bradley D. Vince, DO, Vince & Associates Clinical Research, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2013

Primary Completion (Anticipated)

August 1, 2013

Study Completion (Anticipated)

December 1, 2013

Study Registration Dates

First Submitted

June 17, 2013

First Submitted That Met QC Criteria

July 9, 2013

First Posted (Estimate)

July 12, 2013

Study Record Updates

Last Update Posted (Estimate)

July 12, 2013

Last Update Submitted That Met QC Criteria

July 9, 2013

Last Verified

June 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RIHSC #13-019D

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Epilepsy

Clinical Trials on Divalproex Sodium Extended-release 250mg

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe